Previous 10 | Next 10 |
home / stock / cyccp / cyccp news
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-complianc...
2023-11-13 19:32:06 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO ...
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, N.J., Nov. 13, 202...
BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Mond...
2023-10-18 11:22:58 ET More on Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Call Transcript Historical earnings data for Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Dividend scorecard for Cyclacel Pharmaceutica...
2023-08-09 21:42:12 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Conference Call Aug 9, 2023 4:30 PM ET Company Participants Grace Kim - Investor Relations Spiro Rombotis - President and Chief Executive Officer Mark Kirschbaum - Senior Vice President ...
- Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2 Data with Oral Fadraciclib - - Signals of Single-agent Efficacy with Oral Plogosertib - - Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGH...
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wed...
2023-05-11 19:59:08 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu...
- Key Catalysts ahead with multiple Value Generating Readouts - - Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib - - Advancing single-agent Efficacy with Differentiated Oral Plogosertib - - Adds to Balance Sheet with non-dilutive $4.7 million fro...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the &...
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesd...
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced...